301–1228 Hamilton Street
Vancouver, BC V6B 6L2
Canada
604-564-9244
https://www.alphacognition.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees:
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Michael E. McFadden | CEO & Director | 655.19k | N/A | 1967 |
Mr. Kenneth Anthony Cawkell B.A., LL.B. | Founder, Special Advisor, Corporate Secretary & Director | 97.23k | N/A | 1951 |
Mr. Donald A. Kalkofen B.A. | Chief Financial Officer | 546.1k | 100.44k | 1964 |
Ms. Lauren D'Angelo M.B.A. | Chief Operating Officer | 466.26k | N/A | N/A |
Dr. Denis G. Kay Ph.D. | Chief Scientific Officer | 180k | N/A | 1957 |
Ms. Colleen Johns | Senior Vice President of Product Development | N/A | N/A | N/A |
Alpha Cognition Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062, an acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer's type and mild traumatic brain injury; ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.
Alpha Cognition Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.